Leniolisib-d5

• Description :

  Leniolisib-d5 is a deuterated labeled Leniolisib[1]. Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

• Product Name Alternative :

  CDZ173-d5

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Isotope-Labeled Compounds; PI3K

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Others; PI3K/Akt/mTOR

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Purity :

  98.78

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  COC1=C(C(F)(F)F)C=C(N2CC(C(N[C@H]3CCN(C(C([2H])([2H])C([2H])([2H])[2H])=O)C3)=NC=N4)=C4CC2)C=N1

• Molecular Formula :

  C21H20D5F3N6O2

• Molecular Weight :

  455.49

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8 (9) :975-980. |[2]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported